The goal of this project is to focus on one animal model of individual differences in emotional responsiveness to the environment, and to begin to define some of the critical variables that contribute to those behavioral differences. This behavioral model characterizes responsiveness to novelty and other anxiety-provoking situations and distinguishes animals on the basis of whether they are high responders (HR) or low responders (LR). We have already demonstrated that these two groups of rats show significant differences in their stress circuits, in patterns of gene expression in their brain and in their behavioral responsiveness to psychosocial stress. There is ample evidence that the serotonergic system is critical in stress and depression and is the target of an important class of anti-depressants. However, the role of this system in determining individual differences in emotionality remains unknown. In order to further define the neuronal phenotype of these differing animals, this project will use in situ hybridization tools to characterize the expression of serotonergic genes in the hippocampus and cortex of the two groups of animals with different emotional reactivity. It will employ pharmacological tools by locally microinjecting specific 5HT receptor agonists and antagonists in order to link the observed difference in serotonin receptor gene expression to individual differences in anxiety responses. It will also investigate the differential effects of chronic social stress on the neuronal phenotypes of HR and LR animals, and will investigate the actions of multiple classes of anti-depressants on reversing these stress effects. In addition to focusing to focusing on an obvious """"""""candidate' system, this project will use microarray technology to uncover """"""""novel candidates"""""""", i.e. other genes that are associated with this behavioral phenotype and are sensitive to chronic social stress. This work will begin to delineate how particular molecules and brain circuits contribute to differences in emotional reactivity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
2P01MH042251-16
Application #
6589934
Study Section
Special Emphasis Panel (ZMH1)
Project Start
2002-04-16
Project End
2006-11-30
Budget Start
Budget End
Support Year
16
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hillhouse, Todd M; Porter, Joseph H (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23:1-21
Meyers, K K; Crane, N A; O'Day, R et al. (2015) Smoking history, and not depression, is related to deficits in detection of happy and sad faces. Addict Behav 41:210-7
Lohoff, F W; Hodge, R; Narasimhan, S et al. (2014) Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry 19:129-39
Tomita, Hiroaki; Ziegler, Mary E; Kim, Helen B et al. (2013) G protein-linked signaling pathways in bipolar and major depressive disorders. Front Genet 4:297
Votruba, Kristen L; Langenecker, Scott A (2013) Factor structure, construct validity, and age- and education-based normative data for the Parametric Go/No-Go Test. J Clin Exp Neuropsychol 35:132-46
Turner, Cortney A; Watson, Stanley J; Akil, Huda (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:160-74
Vederman, Aaron C; Weisenbach, Sara L; Rapport, Lisa J et al. (2012) Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder. Cortex 48:1027-34
Turner, Cortney A; Clinton, Sarah M; Thompson, Robert C et al. (2011) Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Natl Acad Sci U S A 108:8021-5
Mickey, Brian J; Zhou, Zhifeng; Heitzeg, Mary M et al. (2011) Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 68:158-66

Showing the most recent 10 out of 75 publications